应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03880 泰德医药
交易中 07-17 13:34:04
32.850
-1.350
-3.95%
最高
35.000
最低
32.500
成交量
24.97万
今开
34.250
昨收
34.200
日振幅
7.31%
总市值
46.65亿
流通市值
24.18亿
总股本
1.42亿
成交额
833.43万
换手率
0.34%
流通股本
7,360万
市净率
13.39
ROE
20.67%
每股收益
0.00
52周最高
40.100
52周最低
28.100
市盈率
--
股息
0.00
股息收益率
0.00
ROA
5.25%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
泰德医药07月15日主力净流出96.4万元 散户资金买入
市场透视 · 07-15 08:15
泰德医药07月15日主力净流出96.4万元 散户资金买入
泰德医药07月11日获主力加仓109.5万元
市场透视 · 07-11
泰德医药07月11日获主力加仓109.5万元
近期国内融资|泰德医药、拨康视云港交所上市
药菓 · 07-07
近期国内融资|泰德医药、拨康视云港交所上市
泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间
动脉网 · 07-01
泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间
风口上的卖铲人,全球第三大多肽CRDMO港股上市
动脉网 · 07-01
风口上的卖铲人,全球第三大多肽CRDMO港股上市
欢迎IFBH(HK.6603)、云知声智能科技股份(HK.9678)和泰德医药(浙江)股份(HK.3880)今日在港上市
香港交易所脈搏/HKExPulse · 06-30
欢迎IFBH(HK.6603)、云知声智能科技股份(HK.9678)和泰德医药(浙江)股份(HK.3880)今日在港上市
异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好
异动解读 · 06-30
异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好
异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧
异动解读 · 06-30
异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧
一家CRDMO港股上市,CRO项目1217个
生物药大时代 · 06-30
一家CRDMO港股上市,CRO项目1217个
异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷
异动解读 · 06-30
异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷
新股定价|泰德医药公开发售超购300倍,一手中签50%
老虎资讯综合 · 06-29
新股定价|泰德医药公开发售超购300倍,一手中签50%
新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元
智通财经 · 06-27
新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元
老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”
老虎资讯综合 · 06-27
老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”
多肽CRDMO新贵赴港IPO
药智网 · 06-27
多肽CRDMO新贵赴港IPO
【新股IPO】中泰国际予泰德医药IPO评分70分 予“申购”评级
金吾资讯 · 06-24
【新股IPO】中泰国际予泰德医药IPO评分70分 予“申购”评级
【投融资动态】泰德医药基石投资轮融资,融资额1000万美元,投资方为石药集团、微光创投等
证券之星 · 06-23
【投融资动态】泰德医药基石投资轮融资,融资额1000万美元,投资方为石药集团、微光创投等
医疗健康领域投融资日报(6月20日):浙江泰德医药完成1000万美元Pre-IPO融资
亿欧网 · 06-20
医疗健康领域投融资日报(6月20日):浙江泰德医药完成1000万美元Pre-IPO融资
泰德医药:创新药牛市+减肥药卖铲人概念,能打吗?
财经自媒体 · 06-20
泰德医药:创新药牛市+减肥药卖铲人概念,能打吗?
新股招股|泰德医药今起招股,一手入场费约3090.85港元
老虎资讯综合 · 06-20
新股招股|泰德医药今起招股,一手入场费约3090.85港元
泰德医药(03880)6月20日至6月25日招股 预计6月30日上市
智通财经 · 06-19
泰德医药(03880)6月20日至6月25日招股 预计6月30日上市
加载更多
公司概况
公司名称:
泰德医药
所属市场:
SEHK
上市日期:
2025-06-30
主营业务:
泰德医药(浙江)股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构(CRO)服务,即多肽新化学实体(NCE)发现合成、合约开发及生产机构(CDMO)服务即多肽化学、制造及控制(CMC)开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分(APIs),而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。
发行价格:
30.600
{"stockData":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":32.85,"timestamp":1752730399495,"preClose":34.2,"halted":0,"volume":249700,"delay":0,"floatShares":73598888,"shares":142000000,"eps":0,"marketStatus":"交易中","change":-1.35,"latestTime":"07-17 13:34:04","open":34.25,"high":35,"low":32.5,"amount":8334265,"amplitude":0.073099,"askPrice":32.95,"askSize":2700,"bidPrice":32.85,"bidSize":2200,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752739800000},"marketStatusCode":2,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":34.2,"openAndCloseTimeList":[[1752715800000,1752724800000],[1752728400000,1752739200000]],"volumeRatio":0.734649,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03880","defaultTab":"news","newsList":[{"id":"2551168328","title":"泰德医药07月15日主力净流出96.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2551168328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551168328?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:15","pubTimestamp":1752567310,"startTime":"0","endTime":"0","summary":"07月15日, 泰德医药股价跌3.25%,报收35.75元,成交金额2693.3万元,换手率0.98%,振幅15.16%,量比1.28。泰德医药今日主力资金净流出96.4万元,上一交易日主力净流入851.9万元。该股近5个交易日上涨14.79%,主力资金累计净流入1105.5万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入1939.3万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715164614a6aab19e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715164614a6aab19e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2550540936","title":"泰德医药07月11日获主力加仓109.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550540936","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550540936?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:15","pubTimestamp":1752221710,"startTime":"0","endTime":"0","summary":"07月11日, 泰德医药股价涨1.96%,报收31.25元,成交金额937.8万元,换手率0.41%,振幅3.59%,量比0.63。泰德医药今日主力资金净流入109.5万元,连续7日净流入,上一交易日主力净流入11.1万元。该股近5个交易日下跌0.95%,主力资金累计净流入1330.3万元;近20日主力资金累计净流入1183.8万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711165440a6a368e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711165440a6a368e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2549539224","title":"近期国内融资|泰德医药、拨康视云港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539224","media":"药菓","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549539224?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:01","pubTimestamp":1751882490,"startTime":"0","endTime":"0","summary":"公司致力于开发新一代治疗性和诊断用抗体药物,通过自主研发的智能抗体技术,能够高效设计并生成满足临床需求的抗体,同时显著降低治疗性抗体的开发成本。禾元生物成立于2006年,以植物表达动物蛋白的方式,生产药品、药用辅料及科研试剂。这也是重启科创板第五套上市标准后,首家按此标准成功过会的IPO企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","03880"],"gpt_icon":1},{"id":"2548025873","title":"泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2548025873","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548025873?lang=zh_cn&edition=full","pubTime":"2025-07-01 10:44","pubTimestamp":1751337840,"startTime":"0","endTime":"0","summary":"泰德医药,多肽CRDMO领域龙头,6月30日在港交所上市,计划扩大在美国和中国的设施,以显著提升服务能力和产能,迎接更大成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701110544953200a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"2df76ee7ea8420c4a03b3e945881ac96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701110544953200a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2548044879","title":"风口上的卖铲人,全球第三大多肽CRDMO港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548044879","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548044879?lang=zh_cn&edition=full","pubTime":"2025-07-01 08:04","pubTimestamp":1751328243,"startTime":"0","endTime":"0","summary":"6月30日,专注于多肽CRDMO的泰德医药成功登陆港交所。经过多年发展,泰德医药已经成为全球多肽CRDMO领域的重要玩家。02千亿多肽CRDMO赛道迎来黄金发展期GLP-1的爆火显著推动了全球多肽CRDMO市场的增长。对第三方服务供应商的依赖导致全球多肽CRDMO市场快速增长,按销售收入计,该市场的规模由2018年的16亿美元增加至2023年的31亿美元,复合年增长率为14.8%,预计于2032年将进一步增长至188亿美元,复合年增长率为22.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701081418a4c78e8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701081418a4c78e8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","HSCEI","03880"],"gpt_icon":1},{"id":"2548873238","title":"欢迎IFBH(HK.6603)、云知声智能科技股份(HK.9678)和泰德医药(浙江)股份(HK.3880)今日在港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548873238","media":"香港交易所脈搏/HKExPulse","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548873238?lang=zh_cn&edition=full","pubTime":"2025-06-30 19:05","pubTimestamp":1751281500,"startTime":"0","endTime":"0","summary":"欢迎IFBH(6603)、云知声智能科技股份有限公司 (9678) 和泰德医药(浙江)股份有限公司(3880)今日加入香港市场!IFBH是一家植根泰国的即饮饮料及即食食品公司。云知声智能科技股份有限公司是一家AI解决方案提供商,主要在中国销售用于日常生活及医疗相关应用场景的对话式AI产品及解决方案。泰德医药(浙江)股份有限公司是一家专注于多肽类药物研发与生产的合约研究,开发及生产机构(CRDMO)。恭喜成功上市!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4ODAxMzAyMA==&mid=2664979326&idx=2&sn=970d64ae987e25858f46d3fae97d6926&chksm=8b1c5acdbc6bd3db6ce7e7ea45d9dd625aebe1132ed8e8d1396e3cba9fc653bdf2d02a9f749a#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["03880","09678","06603"],"gpt_icon":0},{"id":"1151587210","title":"异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1151587210","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151587210?lang=zh_cn&edition=full","pubTime":"2025-06-30 13:06","pubTimestamp":1751260007,"startTime":"0","endTime":"0","summary":"6月30日,全球第三大专注于多肽的CRDMO服务商泰德医药在港交所挂牌上市。截至发稿,该股盘中大涨5.23%,引发市场关注。泰德医药此次IPO获得投资者热烈追捧,公开发售部分获301.15倍超额认购。上市首日开盘价为30.3港元,略低于发行价,但随后股价迅速拉升。分析人士认为,泰德医药股价上涨主要有以下几个原因:首先,公司是全球第三大专注于多肽的CRDMO,市场份额达1.5%,在行业中具有领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ec850e8897536c756ef52d3b59f79c38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1170125532","title":"异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1170125532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170125532?lang=zh_cn&edition=full","pubTime":"2025-06-30 13:06","pubTimestamp":1751259991,"startTime":"0","endTime":"0","summary":"6月30日,泰德医药在港交所正式挂牌上市,盘中股价大涨5.23%。截至下午1点04分,泰德医药报32.2港元,总市值达45.7亿港元。分析人士认为,泰德医药股价的强势表现反映了投资者对公司在快速增长的多肽CRDMO市场中的领先地位的认可,以及对其未来在GLP-1等热门领域发展潜力的看好。随着全球多肽药物市场的持续扩张,泰德医药有望受益于行业增长红利,进一步巩固其市场地位。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ec850e8897536c756ef52d3b59f79c38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"2547566060","title":"一家CRDMO港股上市,CRO项目1217个","url":"https://stock-news.laohu8.com/highlight/detail?id=2547566060","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547566060?lang=zh_cn&edition=full","pubTime":"2025-06-30 12:32","pubTimestamp":1751257920,"startTime":"0","endTime":"0","summary":"泰德医药发售价为每股H股30.60港元,市值43.49亿港元。全球多肽CRDMO市场约有150名多肽CRDMO服务供应商。其专注于多肽的合约研究、开发及生产机构,是全球第三大多肽CRDMO。截至2024年12月31日,泰德医药拥有1217个在研CRO项目、332个在研CDMO项目。2024年,CDMO服务贡献3.3亿元收入,占比74.6%,美国市场营收占比55%,远超内地市场的21.4%。目前,泰德医药正推进与7位客户的9个NCE GLP-1项目开发,涵盖临床前至临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","03880","HSTECH"],"gpt_icon":1},{"id":"1133551242","title":"异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷","url":"https://stock-news.laohu8.com/highlight/detail?id=1133551242","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133551242?lang=zh_cn&edition=full","pubTime":"2025-06-30 09:36","pubTimestamp":1751247406,"startTime":"0","endTime":"0","summary":"6月30日,全球第三大专注于多肽的CRDMO泰德医药在港交所主板挂牌上市,但开市后股价表现不佳。截至上午9:34,泰德医药股价大跌5.07%,显示出投资者对该新股的谨慎态度。泰德医药此次IPO发行价为每股30.60港元,共发行1680万股股份。然而,上市首日股价的下跌反映出市场情绪的快速转变。泰德医药计划将此次IPO募集的资金用于扩大在美国和中国的产能,发展寡核苷酸业务,以及在欧洲设立销售及售后服务办事处。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2df76ee7ea8420c4a03b3e945881ac96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1107008937","title":"新股定价|泰德医药公开发售超购300倍,一手中签50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107008937","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107008937?lang=zh_cn&edition=full","pubTime":"2025-06-30 07:54","pubTimestamp":1751241271,"startTime":"0","endTime":"0","summary":"6月30日, $泰德医药$公布配发结果,每股定价30.60港元,共发行1680万股股份,每手100股,今日正式上市。上一交易日,泰德医药暗盘低开,收涨1.8%,报31.15港元,成交额8263.13万港元,总市值44.17亿港元。公开发售阶段泰德医药获301.15倍认购,经重新分配后,公开发售的发售股份最终数目为840万股股份,占发售股份总数的约50%。泰德医药主要提供CRO服务,即多肽NCE发现合成;及CDMO服务,即多肽CMC开发以及商业化生产。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股定价|泰德医药公开发售超购300倍,一手中签50%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":1},{"id":"2546974197","title":"新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546974197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546974197?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:21","pubTimestamp":1751012476,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,泰德医药(03880)将于6月30日(星期一)在香港挂牌。截至发稿,暗盘交易显示报价31.25港元,较招股价30.6港元上涨2.12%,每手100股,不计手续费,每手赚65港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"gpt_icon":0},{"id":"1169056197","title":"老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”","url":"https://stock-news.laohu8.com/highlight/detail?id=1169056197","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169056197?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:17","pubTimestamp":1751012226,"startTime":"0","endTime":"0","summary":"有望受益于“减肥神药”行情。","market":"hk","thumbnail":"https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":0},{"id":"2546760566","title":"多肽CRDMO新贵赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2546760566","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546760566?lang=zh_cn&edition=full","pubTime":"2025-06-27 11:56","pubTimestamp":1750996582,"startTime":"0","endTime":"0","summary":"6月的港股创新药市场再掀波澜——继核药龙头先通医药递交上市申请后,专注于多肽领域的CRDMO企业泰德医药于6月20日正式开启招股,预计6月30日登陆港交所主板。这家全球第三大多肽CRDMO企业的IPO进程,不仅标志着中国医药外包产业在细分领域的突破,更折射出多肽药物黄金赛道的资本热度。千亿赛道的黄金驱动力泰德医药所处的多肽CRDMO赛道,正迎来前所未有的发展机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":1},{"id":"2545474803","title":"【新股IPO】中泰国际予泰德医药IPO评分70分 予“申购”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474803","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545474803?lang=zh_cn&edition=full","pubTime":"2025-06-24 13:31","pubTimestamp":1750743072,"startTime":"0","endTime":"0","summary":"2024年收入同比增加31.3%,股东净利润同比增加21.0%,资产负债表健康。由于医药研发与生产外包行业的业务中,多肽药物的增速明显快于该行业的总体水平,因此该机构认为专注于多肽药物的企业应存在估值溢价,港股企业可比性不强,因此该机构也参考A股。公司招股价对应的估值较A股同业有折让,因此该机构认为估值仍合理,而且公司保荐人往绩记录良好,新股市场畅旺,给予“申购”评级及70分的评分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062413314095290c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062413314095290c0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":1},{"id":"2545169764","title":"【投融资动态】泰德医药基石投资轮融资,融资额1000万美元,投资方为石药集团、微光创投等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545169764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545169764?lang=zh_cn&edition=full","pubTime":"2025-06-23 19:25","pubTimestamp":1750677940,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP于6月19日公布的信息整理,泰德医药(浙江)股份有限公司基石投资轮融资,融资额1000万美元,参与投资的机构包括石药集团,微光创投。泰德医药主要提供CRO服务,即多肽NCE发现合成;及CDMO服务,即多肽CMC开发以及商业化生产。集团的服务主要专注于向客户提供API,而非药品。然后,集团的客户会将API与辅料混合,形成药品的最终剂型,并确定适当的剂型、给药途径及配方,然后将最终药品用于其临床试验或商业销售。数据来源:天眼查APP以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062300026474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["IE00B031HY20.USD","LU1008478684.HKD","SG9999004220.SGD","LU0072913022.USD","LU1960683339.HKD","LU0140636845.USD","BK1521","LU1226287529.USD","IE00B543WZ88.USD","LU0501845795.SGD","03880","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1226287792.SGD","LU1807302812.USD","BK1515","01093","IE0008368742.USD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1951186391.HKD","LU0880133367.SGD","IE0008369823.USD","LU1226287875.USD","LU0067412154.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1226288170.HKD","LU1993786604.SGD","BK1191","LU1152091754.HKD"],"gpt_icon":0},{"id":"2545484420","title":"医疗健康领域投融资日报(6月20日):浙江泰德医药完成1000万美元Pre-IPO融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2545484420","media":"亿欧网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545484420?lang=zh_cn&edition=full","pubTime":"2025-06-21 07:00","pubTimestamp":1750460400,"startTime":"0","endTime":"0","summary":"联影智能总部位于中国上海市,是一家高端医疗影像设备研发生产商;3.北检检测完成1000万人民币A轮融资,该公司总部位于中国山东省,是一家生物安全与动物实验室。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622025141a716579f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622025141a716579f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2544120563","title":"泰德医药:创新药牛市+减肥药卖铲人概念,能打吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2544120563","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544120563?lang=zh_cn&edition=full","pubTime":"2025-06-20 19:53","pubTimestamp":1750420380,"startTime":"0","endTime":"0","summary":"今日,港交所一口气批了3只新股,分别是IFBH、云知声和泰德医药。简而言之,泰德医药是帮助创新药公司做临床实验及代工生产药物的,与药明康德、凯莱英等公司是竞争对手。信邦制药因此计提商誉减值15.37亿元,归母净亏损12.97亿元,为上市以来首次亏损。由此来看,泰德医药算不上好公司,无非是赶上多肽药的爆发。不过,从今日药捷安康暗盘大涨68.8%、佰泽医疗涨超25%来看,医药股仍然受到投资者追捧,泰德医药或将延续创新药新股神话!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-20/doc-infatrke3836523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","159992","03880","BK1161"],"gpt_icon":1},{"id":"1173753255","title":"新股招股|泰德医药今起招股,一手入场费约3090.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173753255","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173753255?lang=zh_cn&edition=full","pubTime":"2025-06-20 08:46","pubTimestamp":1750380364,"startTime":"0","endTime":"0","summary":"6月20日,$泰德医药$于2025年6月20日至6月25日招股,公司拟发售1680万股,香港发售占10%,国际发售占90%。每股发售价28.4-30.6港元,每手100股,预期股份将于6月30日开始在联交所买卖。申购阶梯:每手100股,入场费3090.85港元。乙组门槛为20万股,申购所需资金约618.17万港元。公司为客户提供符合全球主要市场监管规定的多肽类药物开发、生产、 CMC申报支持服务。所得款项净额的约4.1%将用于扩张中国的产能。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股|泰德医药今起招股,一手入场费约3090.85港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":0},{"id":"2544948871","title":"泰德医药(03880)6月20日至6月25日招股 预计6月30日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544948871","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544948871?lang=zh_cn&edition=full","pubTime":"2025-06-20 07:04","pubTimestamp":1750374293,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰德医药 于2025年6月20日至6月25日招股,公司拟发售1680万股,香港发售占10%,国际发售占90%。每股发售价28.4-30.6港元,每手100股,预期股份将于2025年6月30日(星期一)开始在联交所买卖。公司已在超过50个国家建立稳定的客户关系和服务范围,其中包括中国、美国、日本、欧洲、韩国及澳大利亚等主要市场。公司为客户提供符合全球主要市场监管规定的多肽类药物开发、生产、 CMC申报支持服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","09939","159938","03880"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medtideinc.com","stockEarnings":[{"period":"1week","weight":0.1122},{"period":"1month","weight":0.1176},{"period":"ytd","weight":0.1176}],"compareEarnings":[{"period":"1week","weight":0.0262},{"period":"1month","weight":0.019},{"period":"3month","weight":0.1459},{"period":"6month","weight":0.2519},{"period":"1year","weight":0.383},{"period":"ytd","weight":0.2222}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"泰德医药(浙江)股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构(CRO)服务,即多肽新化学实体(NCE)发现合成、合约开发及生产机构(CDMO)服务即多肽化学、制造及控制(CMC)开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分(APIs),而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。","exchange":"SEHK","name":"泰德医药","nameEN":"MEDTIDE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰德医药,03880,泰德医药股票,泰德医药股票老虎,泰德医药股票老虎国际,泰德医药行情,泰德医药股票行情,泰德医药股价,泰德医药股市,泰德医药股票价格,泰德医药股票交易,泰德医药股票购买,泰德医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}